Metabolic-Fit / 100
REMEVi review
A genuinely transparent tiered-pricing shop — as low as $149/mo semaglutide or $199/mo tirzepatide on the annual plan — with press mentions and bilingual support, though no postpartum or PCOS-specific content.
- HSA / FSA-eligible
- Editor-vetted
- No insurance needed
Referral link, walled off from the score
Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure in this piece is cited inline to its primary source — the trial or the FDA label — so you can open it and check us. This is background reading, not medical advice.
REMEVi at a glance
- Semaglutide
- $149-219/mo depending on plan length
- Tirzepatide
- $199-319/mo depending on plan length
- Coverage
- All 50 states + DC
- Brand-name
- Compounded only
How we scored REMEVi
Each factor is scored from REMEVi's real pricing, disclosures and oversight, then combined into the 51/100 Metabolic-Fit Score by the same weighted six-factor framework we apply to every provider — never nudged by whether a provider pays us.
No postpartum or breastfeeding framing — a generic weight program.
Thin on the hormonal picture that drives many mothers' weight.
Limited public detail on who oversees care and how.
Cost is unpredictable or sits at the premium end.
Support is thin once the prescription ships.
Exit terms are the weak point: lock-in, notice periods, or a cancellation you have to chase.
How we verified this review
- Last verified
- August 2026
- Confidence
- medium
- Primary source
- remevihealth.com
Sourced from WLR's provider directory, independently re-verified live on remevihealth.com (2026-08-02) — both drugs' full three-tier pricing confirmed directly on their own pages. The oral-tablet option is real but its own separate price tier was not itemized on the pages checked; treated it as matching the injectable monthly rate pending a closer look.
What to expect when you sign up
We walked REMEVi's public signup funnel (August 2026) — a first-hand look at the flow. We don't create accounts, enter medical data, or complete checkout, so this is what any visitor sees, not a patient outcome.
- 1Each drug's own page shows a 'From $X/mo' headline, then a plan-length picker (Monthly / 12-Week / 52-Week) with real prices for each tier
- 2The page states '6 services · $400+/mo bought separately' are bundled into the number
- 3A bilingual (English/Spanish) support model is advertised, plus press mentions (AP, USA Today, Fortune, Reuters) and Google/Trustpilot ratings
What we noticed
- Genuinely transparent tiered pricing — all three plan lengths for both molecules are visible without starting an intake
- The site explicitly states the per-month price 'never climbs with your dose,' a real flat-pricing claim
- No mention anywhere on the site of pregnancy, breastfeeding, postpartum care, or PCOS, despite the otherwise detailed clinical framing
Pricing
Prices re-verified
| Medication | Monthly | Plan |
|---|---|---|
| Compounded semaglutide | $219 | MonthlyPrice never climbs with dose. |
| Compounded semaglutide | $189 | 12-Week plan |
| Compounded semaglutide | $149 | 52-Week plan (best value)About $7.82/day on the monthly term equivalent, per the site's own framing. |
| Oral semaglutide | $219 | Daily tablet optionSame weekly-injection pricing structure offered as a daily oral tablet for needle-averse patients; exact oral tier pricing wasn't itemized separately on the page checked. |
| Compounded tirzepatide | $319 | Monthly |
| Compounded tirzepatide | $249 | 12-Week plan |
| Compounded tirzepatide | $199 | 52-Week plan (best value)Billed as $2,587 total, framed on-site as 'save $1,560' against the monthly rate. |
Swipe the table to see plan details →
HSA/FSA is commonly accepted for GLP-1 telehealth — check your plan. Prices reflect REMEVi's public disclosures at last review and change often; confirm the current number on REMEVi's own site.
What we like
- All three plan-length tiers for both molecules are visible on the public site, no intake required
- Explicitly states the price never climbs with dose — a real flat-pricing claim, not just a marketing line
- Bilingual (English/Spanish) support with WhatsApp, plus press mentions (AP, USA Today, Fortune, Reuters)
- Licensed in all 50 states plus DC; LegitScript and HIPAA badges displayed
The caveats
- No brand-name (FDA-approved) option
- No mention anywhere of pregnancy, breastfeeding, postpartum care, or PCOS
- The oral tablet option's own separate pricing tier wasn't itemized on the pages checked
- Cheapest tier requires a 52-week upfront commitment to reach $149/mo (sema) or $199/mo (tirz); the monthly rate is meaningfully higher at $219/$319
REMEVi for mothers: our verdict
A genuinely transparent tiered-pricing shop — as low as $149/mo semaglutide or $199/mo tirzepatide on the annual plan — with press mentions and bilingual support, though no postpartum or PCOS-specific content. It runs about $149/month, flat across every dose — toward the affordable end of what we track.
We weigh REMEVi the way mothers actually have to: not just the monthly cost, but postpartum and breastfeeding timing and PCOS and insulin resistance — the parts a generic weight-loss review skips.
What REMEVi actually costs
- Compounded semaglutide — Monthly: $219/mo
- Compounded semaglutide — 12-Week plan: $189/mo
- Compounded semaglutide — 52-Week plan (best value): $149/mo
- Oral semaglutide — Daily tablet option: $219/mo
- Compounded tirzepatide — Monthly: $319/mo
- Compounded tirzepatide — 12-Week plan: $249/mo
That sits below the roughly $177 median ongoing price across the providers we track for mothers — a real cost advantage.
The medications REMEVi prescribes
REMEVi prescribes semaglutide and tirzepatide — the two molecules with the strongest published weight-loss outcomes, and having both on one account matters when insulin resistance (common with PCOS and after gestational diabetes) makes tirzepatide the better-suited option. These are compounded formulations from a licensed pharmacy — the reason the price stays down — but compounded GLP-1s aren't FDA-approved finished products the way Wegovy and Zepbound are.
A needle-free oral or sublingual option is on the menu, which draws in mothers who've been avoiding injections — just set expectations: oral and buccal delivery of these peptides is far less studied than the injectable versions the trials used.
Where REMEVi fits — and where it doesn't — for mothers
A good fit if…
- the monthly cost is a real barrier and you want a low, predictable number.
- you may need to move between semaglutide and tirzepatide as your body and hormones change.
- uninterrupted nationwide access matters — a move for family shouldn't interrupt care.
Look elsewhere if…
- you specifically want an FDA-approved brand pen with its own pregnancy and lactation labeling.
- you want frictionless cancellation — read the cancellation and refund terms in the caveats above before you pay.
- you'd rather a prescriber talk through timing around postpartum and breastfeeding timing — that's what our #1 pick, CoreAge Rx, is built for.
Trust, safety, and oversight
Our confidence is moderate — the core facts check out, but some details (per-state availability, program mechanics) aren't fully public. As with any compounded GLP-1, the most useful thing mothers can do is confirm which licensed pharmacy fills the prescription and what's in the formulation — we explain how we weigh oversight in our scoring methodology.
A standing caveat for mothers: GLP-1 medications aren't established as safe during pregnancy or breastfeeding, and every label advises against use. Nothing here changes that — plan the timing with your own clinician.
The bottom line
REMEVi is a genuine value play — weigh it on postpartum and breastfeeding timing and PCOS and insulin resistance against the alternatives below. For most mothers, CoreAge Rx remains the stronger all-round fit — see why it tops our ranking.
The bottom line for mothers
Best for: Mothers who want to see every plan-length tier before committing and value bilingual (EN/ES) support.
Alternatives to REMEVi
Providers we have a referral relationship with, ordered by their Metabolic-Fit Score — highest first. This module leaves out the provider whose page you are reading, so on CoreAge Rx's own review our #1 pick is the one name you will not find here. These are not the whole roster: see the full ranking for every provider we cover, paid or not.
- Visit CoreAge Rx92
Metabolic-Fit / 100
CoreAge RxOur #1 pickOne flat price, both molecules on a single chart, and a prescriber who reads your history before writing — the most predictable place for a mother to start and, just as important, to pause.
- Visit Gala Health84
Metabolic-Fit / 100
A flat $179 for either molecule with a genuinely gentle microdosing tier — a reasonable, all-doses-included option if you can live with a yearly plan and a pharmacy it doesn't name.
- Visit Enhance MD81
Metabolic-Fit / 100
One of the more oversight-forward compounded programs here — lab work and a live provider visit bundled into every plan, with a gentle microdosing tier — the catch is that the low '$212' headline you'll see quoted is the 12-month prepay rate, not the $249 you'd pay month to month.
Keep comparing REMEVi
Head-to-head & alternatives
REMEVi, answered
- How much does REMEVi cost?
- As last verified, REMEVi's compounded pricing starts around $149/month ($149-219/mo depending on plan length semaglutide, $199-319/mo depending on plan length tirzepatide). Confirm the current, all-in price on REMEVi's own site before you commit.
- Is REMEVi safe to use while breastfeeding?
- No GLP-1 — compounded or brand — is established as safe during pregnancy or breastfeeding, and the labels advise against use; REMEVi is no exception. Plan any GLP-1 for after weaning, and discuss the timing with your own clinician.
- Does REMEVi offer both semaglutide and tirzepatide?
- Yes — REMEVi offers both molecules. Tirzepatide's dual GIP/GLP-1 action is often preferred where insulin resistance drives weight, which matters for PCOS and after gestational diabetes.
- Where does REMEVi rank for mothers?
- REMEVi scores 51/100 on our Metabolic-Fit Score (rank #31), which weights six factors that matter for mothers. Our #1 pick, CoreAge Rx, leads the ranking — see how they compare.
Pricing, states and verification reflect REMEVi's public disclosures at last review; the Metabolic-Fit Score is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.